HPGC Renmintongtai Pharmaceutical (SHSE:600829) DeferredTaxAndRevenue: ¥0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600829 HPGC Renmintongtai Pharmaceutical Corp SHSE:600829
66 GF Score
Price ¥11.83
GF Value ¥8.13
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is HPGC Renmintongtai Pharmaceutical DeferredTaxAndRevenue?

HPGC Renmintongtai Pharmaceutical SHSE:600829 +10.05% 66 DeferredTaxAndRevenue is ¥0 Mil as of Jun. 2026. GuruFocus rates SHSE:600829 with a GF Score™ of 66/100 and a GF Value™ of ¥8.13 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

HPGC Renmintongtai Pharmaceutical's current deferred tax and revenue for the quarter that ended in Jun. 2026 was ¥0 Mil.

HPGC Renmintongtai Pharmaceutical DeferredTaxAndRevenue Related Terms

HPGC Renmintongtai Pharmaceutical DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for HPGC Renmintongtai Pharmaceutical's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HPGC Renmintongtai Pharmaceutical DeferredTaxAndRevenue Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HPGC Renmintongtai Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:600829
66GF Score
HPGC Renmintongtai Pharmaceutical Corp SHSE:600829
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of ¥0 Mil mean?
HPGC Renmintongtai Pharmaceutical (SHSE:600829) has a DeferredTaxAndRevenue of ¥0 Mil as of Jun. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on HPGC Renmintongtai Pharmaceutical.
Is HPGC Renmintongtai Pharmaceutical's DeferredTaxAndRevenue too high?
HPGC Renmintongtai Pharmaceutical's current DeferredTaxAndRevenue is ¥0 Mil. Overall, HPGC Renmintongtai Pharmaceutical has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HPGC Renmintongtai Pharmaceutical's DeferredTaxAndRevenue compare to ZTS?
HPGC Renmintongtai Pharmaceutical's DeferredTaxAndRevenue of ¥0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on HPGC Renmintongtai Pharmaceutical. HPGC Renmintongtai Pharmaceutical's current DeferredTaxAndRevenue is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HPGC Renmintongtai Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, HPGC Renmintongtai Pharmaceutical (SHSE:600829) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.13, compared to a current price of ¥11.83 — trading 45.5% above its estimated fair value. The current DeferredTaxAndRevenue is ¥0 Mil. HPGC Renmintongtai Pharmaceutical's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For HPGC Renmintongtai Pharmaceutical (SHSE:600829), the current DeferredTaxAndRevenue is ¥0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) Overvalued in 2026?

Based on GuruFocus' analysis, HPGC Renmintongtai Pharmaceutical stock appears to be overvalued. The current stock price of ¥11.83 is trading 45.5% above its estimated GF Value™ of ¥8.13. GuruFocus considers HPGC Renmintongtai Pharmaceutical to be Significantly Overvalued.

Key valuation signals for SHSE:600829:

  • DeferredTaxAndRevenue: ¥0 Mil
  • GF Value™: ¥8.13 vs. price of ¥11.83 (45.5% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600829 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HPGC Renmintongtai Pharmaceutical Business Description

Address No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.
66GF Score

Get the complete analysis for SHSE:600829

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.83
Price
¥8.13
GF Value